Tag: Survival

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab

Significant and clinically relevant improvement seen in objective response rate with encorafenib + cetuximab plus mFOLFOX6

Improved overall and lung cancer-specific survival seen for lobectomy, segmentectomy versus wedge resection

Progression-free and overall survival do not differ for patients receiving full-dose, lowered-dose dexamethasone throughout induction

Improved survival seen with perioperative chemotherapy with FLOT versus preoperative chemoradiotherapy

Clinically meaningful improvement seen in progression-free survival for transarterial chemoembolization plus lenvatinib and pembrolizumab

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer

Tool demonstrated generalizability through high predictive performance in international clinical cohort

Findings for primary tumors of 0.8 to 1.0 mm versus those <0.8 mm

Estimated disease-free survival 97.5 ± 1.3 and 90.2 ± 2.3 percent with chemotherapy plus blinatumomab, chemo alone in average-risk patients